Dermapharm SE Arbeit im Labor

Investor Relations

On the Investor Relations page you will find all relevant information about Dermapharm Holding SE on the capital market, our Equity Story as well as Investor Relations publications.

Share

Stock information

ISIN / WKN DE000A2GS5D8 / A2GS5D
Stock exchange symbol / Reuters symbol DMP
Type of Shares bearer shares with no par value (Stückaktien)
First day of tradin 9 February 2018
Number of Shares 53.84 million
Stock Exchanges Regulated Market (Prime Standard) of the Frankfurt Stock Exchange
Index since 23th September 2019
Analysts Harald Hof, Alster Research
Charlotte Friedrichs, Berenberg
Alexander Thiel, Jefferies
Daniel Wendorff, ODDO BHF
Dennis Berzhanin, Pareto Securities
Dr. Daniel Grigat, Stifel
Designated Sponsors Berenberg
Stifel
Paying agent Quirin Privatbank AG

Shareholder structure

Dermapharm SE Infografik Aktionärsstruktur Englisch

Financial Figures

Financial Figures

2021

Revenue EUR million 942.9
Adjusted EBITDA EUR million 351.1
Adjusted EBITDA Margin % 37.2
Unadjusted EBITDA EUR million 354.4
Unadjusted EBITDA Margin % 37.6
Operating income EUR million 298.5
EBT EUR million 293.0
Profit or (loss) for the period EUR million 208.9
Earnings per share EUR 3.89
Dividend EUR 2.17
Balance sheet EUR million 1,407.0
Equity EUR million 499.8
Equity ratio % 35.5
Cash and cash equivalents EUR million 161.4
Net debt EUR million 419.7

2020

Revenue EUR million 793.8
Adjusted EBITDA EUR million 200.7
Adjusted EBITDA Margin % 25.3
Unadjusted EBITDA EUR million 184.5
Unadjusted EBITDA Margin % 23.2
Operating income EUR million 136.9
EBT EUR million 125.3
Profit or (loss) for the period EUR million 85.9
Earnings per share EUR 1.59
Dividend EUR 0.88
Balance sheet EUR million 1,224.40
Equity EUR million 324.6
Equity ratio % 26.5
Cash and cash equivalents EUR million 120.3
Net debt EUR million 486.8

2019

Revenue EUR million 700.9
Adjusted EBITDA EUR million 177.6
Adjusted EBITDA Margin % 25.3
Unadjusted EBITDA EUR million 168.8
Unadjusted EBITDA Margin % 24
Operating income EUR million 119.5
EBT EUR million 110.1
Profit or (loss) for the period EUR million 77.8
Earnings per share EUR 1.43
Dividend EUR 0.8
Balance sheet EUR million 1,044.90
Equity EUR million 284.5
Equity ratio % 27.2
Cash and cash equivalents EUR million 115
Net debt EUR million 465.4

2018

Revenue EUR million 572.4
Adjusted EBITDA EUR million 143.4
Adjusted EBITDA Margin % 25.1
Unadjusted EBITDA EUR million 139.6
Unadjusted EBITDA Margin % 24.4
Operating income EUR million 107.5
EBT EUR million 104.2
Profit or (loss) for the period EUR million 75.2
Earnings per share EUR 1.41
Dividend EUR 0.77
Balance sheet EUR million 704.6
Equity EUR million 256.1
Equity ratio % 36.3
Cash and cash equivalents EUR million 212.5
Net debt EUR million 95.2

2017

Revenue EUR million 467.1
Adjusted EBITDA EUR million 112.9
Adjusted EBITDA Margin % 24.2
Unadjusted EBITDA EUR million 110.2
Unadjusted EBITDA Margin % 23.6
Operating income EUR million 92.1
EBT EUR million 88
Profit or (loss) for the period EUR million 77.7
Earnings per share EUR 1.56
Dividend EUR -
Balance sheet EUR million 415.3
Equity EUR million 73.7
Equity ratio % 17.7
Cash and cash equivalents EUR million 6.3
Net debt EUR million 258.5

2016

Revenue EUR million 444.5
Adjusted EBITDA EUR million 102.7
Adjusted EBITDA Margin % 23.1
Unadjusted EBITDA EUR million 102.7
Unadjusted EBITDA Margin % 23.1
Operating income EUR million 86.8
EBT EUR million 82.9
Profit or (loss) for the period EUR million 77
Earnings per share EUR 1.54
Dividend EUR -
Balance sheet EUR million 311.7
Equity EUR million 60.8
Equity ratio % 19.5
Cash and cash equivalents EUR million 3.8
Net debt EUR million 173.7

2015

Revenue EUR million 384.8
Adjusted EBITDA EUR million -
Adjusted EBITDA Margin % -
Unadjusted EBITDA EUR million 84.7
Unadjusted EBITDA Margin % 22
Operating income EUR million 43.3
EBT EUR million 55.3
Profit or (loss) for the period EUR million 52.4
Earnings per share EUR -
Dividend EUR -
Balance sheet EUR million 296.7
Equity EUR million 44.4
Equity ratio % 15
Cash and cash equivalents EUR million 2.8
Net debt EUR million 189.7

2014

Revenue EUR million 391.3
Adjusted EBITDA EUR million -
Adjusted EBITDA Margin % -
Unadjusted EBITDA EUR million 72.4
Unadjusted EBITDA Margin % 18.5
Operating income EUR million 60.8
EBT EUR million 35.5
Profit or (loss) for the period EUR million 33.2
Earnings per share EUR -
Dividend EUR -
Balance sheet EUR million 330.6
Equity EUR million 34
Equity ratio % 10.3
Cash and cash equivalents EUR million 11.6
Net debt EUR million 210.8

Financial Reports & Presentations

Financial Reports & Presentations

2022

Factsheet

A compact summary of all important facts and figures about Dermapharm Holding SE.

To Factsheet 3M 2022

Corporate Governance

Corporate Governance

Compliance

Annual general meeting

Annual general meeting

Annual General Meeting 2021

Annual General Meeting 2020

Annual General Meeting 2019

Sustainability

Sustainability

CSR-Reports

Dermapharm SE Laborant bei der Laborarbeit

GRI-INDEX

Conversion and new buildings for more environmentally friendly production

Dermapharm SE Außenansicht Dermapharm-Gebäude in Grünwald

Consistent growth strategy

In-house product development

The Dermapharm Group develops pharmaceuticals and other healthcare products in its core therapeutic areas at four corporate locations, where experienced experts conduct development and authorisation activities – including designing and funding clinical trials. Once authorisation is granted, newly developed products are generally put into production in-house. In total, the Group manufactures about 90% of the pharmaceutical product portfolio itself.

The focal points of the development work are:

 

  • Expanding the portfolio of off-patent branded pharmaceuticals in dermatology
  • Further developing allergy therapy product range
  • Developing science-based food supplements
  • Developing new phytoextracts
  • Further developing the range of medical devices

Internationalisation

The Dermapharm Group has been operating in Austria, Switzerland, Croatia, Poland and Ukraine for many years now. In order to further expand its business with branded pharmaceuticals and other healthcare products, the Group has formed subsidiaries in the United Kingdom, Italy and Spain. Country-specific portfolios are formed/developed based in each case on a detailed analysis of market conditions, with compounds developed and manufactured by the Group in particular receiving marketing authorisation. This enables the Group to gradually enlarge its portfolio and the respective sales and distribution structures as it expands into new markets. For instance, the Dermapharm Group is expanding into other countries in Europe, Asia and the Americas with its CE-certified and internationally patented medical devices bite away® and Herpotherm®.

Another key aspect of the Group's internationalisation efforts is the acquisition of companies with international operations. The acquisitions of Euromed and Allergopharma stand out as past examples of this approach. At present, the acquisition of Cernelle is making a further contribution to the Group's internationalisation.

M&A activities

Acquiring individual products, portfolios and companies has always been part of Dermapharm's business strategy and a key success factor for its continued growth. Since its formation in 1991, the Group has steadily expanded its product offering through successful acquisitions in Germany and abroad. This includes, for instance, the acquisition of attractive patented medical devices and pharmaceutical manufacturers, which complement the Group's portfolio ideally and expand its offering in growth markets. Another aim when making these types of acquisitions is to further increase the potential of the newly acquired companies by optimising processes and incorporating the companies in the Group's production and logistics structures. The Dermapharm Group continually reviews specific growth opportunities and pursues promising acquisition options that fit its strategic alignment.

Newsletter

We will be happy to include you in our news service!
Please fill out the form and you will receive information on investor relations topics.

Contact information

If you have any further questions, you can contact us at any time. For this purpose, you can contact us in writing via e-mail or directly by telephone. In addition, we offer you the option of subscribing to our IR news service to receive information from Dermapharm Holding SE in a timely manner. You can also find all current dates in the financial calendar.

Dermapharm SE Foto von Britta Hamberger

Britta Hamberger

Head of Investor Relations
& Corporate Communications

Phone: +49 89 641 86 233

britta.hamberger@dermapharm.com

Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany

Dermapharm SE Foto von Christian Weiß

Christian Weiß

Investor Relations
& Corporate Communications

Phone: +49 89 641 86 247

christian.weiss@dermapharm.com

Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany